Farnesoid X receptor inhibits gankyrin in mouse livers and prevents development of liver cancer. - Test2 - elhamkhani - TriplyDB

Farnesoid X receptor inhibits gankyrin in mouse livers and prevents development of liver cancer.

Farnesoid X receptor inhibits gankyrin in mouse livers and prevents development of liver cancer.

http://www.wikidata.org/entity/Q39240990

about

Novel bile acid therapeutics for the treatment of chronic liver diseases Bile acid receptors and nonalcoholic fatty liver disease Correlated high expression of FXR and Sp1 in cancer cells confers a poor prognosis for pancreatic cancer: A study based on TCGA and tissue microarray Bile acid dysregulation, gut dysbiosis, and gastrointestinal cancer.Cooperation of C/EBP family proteins and chromatin remodeling proteins is essential for termination of liver regeneration Upregulation of microRNA-122 by farnesoid X receptor suppresses the growth of hepatocellular carcinoma cells.FXR and liver carcinogenesis FXR induces SOCS3 and suppresses hepatocellular carcinoma.Transcriptional and translational regulation of C/EBPβ-HDAC1 protein complexes controls different levels of p53, SIRT1, and PGC1α proteins at the early and late stages of liver cancer.PSMD10/gankyrin induces autophagy to promote tumor progression through cytoplasmic interaction with ATG7 and nuclear transactivation of ATG7 expression Farnesoid X receptor directly regulates xenobiotic detoxification genes in the long-lived Little mice.LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/STAT3/Akt pathway.Liver diseases and aging: friends or foes?Bile acid receptors as targets for drug development.Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, and Prevention.Gankyrin regulates cell signaling network.FXR-Gankyrin axis is involved in development of pediatric liver cancer.MiR-605 represses PSMD10/Gankyrin and inhibits intrahepatic cholangiocarcinoma cell progression.Interleukin-1β/Iinterleukin-1 receptor-associated kinase 1 inflammatory signaling contributes to persistent Gankyrin activation during hepatocarcinogenesis.Ghrelin deletion protects against age-associated hepatic steatosis by downregulating the C/EBPα-p300/DGAT1 pathway.Proteasome dysregulation in human cancer: implications for clinical therapies.RNA Binding Protein CUGBP1 Inhibits Liver Cancer in a Phosphorylation-Dependent Manner.Activation of CDK4 Triggers Development of Non-alcoholic Fatty Liver Disease.Arctigenin Inhibits Liver Cancer Tumorigenesis by Inhibiting Gankyrin Expression via C/EBPα and PPARα.Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma.PARP1 activation increases expression of modified tumor suppressors and pathways underlying development of aggressive hepatoblastoma

P2860

Q26748613-B43454A4-F5D9-46F4-B7A3-CE3ECD8147A9 Q26775814-A584557C-CB23-493C-B405-2D8379F565A8 Q33779441-58BB2C7D-1A7F-49D5-A5CC-A2921438DA6C Q34425909-432492A9-F669-4CF9-AE95-5241904328D4 Q34791219-2B952B73-2995-434F-A6F7-5DE911136017 Q35990400-1AC46386-F4A4-4372-BCF7-2756911FF6CF Q36063712-E655E891-657C-424F-804F-FEF6E243F63D Q36544161-CEB92CA2-DFC9-4851-B232-D5DB4D34057E Q36850351-1AF71A06-EBA3-4338-9602-E7D87B4521C7 Q37141742-B2B16612-7F0E-43C0-B7E2-9C26740D65AB Q37353652-808B670A-90BE-4533-AF90-91902FA8DECF Q37369888-682B955D-87A1-49F9-A00C-1A010DDAF71C Q38118358-47A76033-C916-4426-BB39-895057708129 Q38132058-A4494D22-6676-45D4-8F69-94BCF7935BD1 Q38584060-8199A960-27BB-45A8-BD79-0F7F4E2B9708 Q38714564-93FC787A-E19A-4F52-8608-305DED3CAC1C Q38768973-1B737204-B24F-48C5-A019-AFE58D5BC90D Q38965092-AAB3D88F-D58D-49B6-8BBB-31A6BADBDFBD Q42184152-888996CC-A801-4CE3-931A-7FE7CCFEFE17 Q47662254-0D7A92AC-AEA6-4A08-B22B-F0E7F554574B Q50077966-13A21DE5-52A5-4ABD-B7EE-22FD506D59E7 Q50970430-90EE1837-B460-4656-A565-2AB4A11B2814 Q51666855-1243CE83-076E-42DD-87CC-09A26E6D309C Q52595227-39AA7EEA-1B5E-40A4-95C1-FA939CA90D5B Q53090136-AC486AFD-2AA4-40CB-8F47-397BC7A663DF Q57144042-42D8983B-08A3-40DF-8F46-9D68BC3D87F9

P2860

Farnesoid X receptor inhibits gankyrin in mouse livers and prevents development of liver cancer.

http://www.wikidata.org/entity/Q39240990

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Farnesoid X receptor inhibits ...... s development of liver cancer.

@en

Farnesoid X receptor inhibits ...... s development of liver cancer.

@nl

type

label

Farnesoid X receptor inhibits ...... s development of liver cancer.

@en

Farnesoid X receptor inhibits ...... s development of liver cancer.

@nl

prefLabel

Farnesoid X receptor inhibits ...... s development of liver cancer.

@en

Farnesoid X receptor inhibits ...... s development of liver cancer.

@nl

P1433

Q39240990-9A702971-5E71-4085-ADEB-623041EBD2CD

P1476

Q39240990-F7E80798-A48C-487F-B553-63876702148D

P2093

Q39240990-02494BF7-9881-4671-919C-F037CD6267AE

Q39240990-33C51AB9-F260-40DF-8B30-E04243BE4A93

Q39240990-365E5CE3-11D7-406D-8937-1354F5BD831D

Q39240990-421815D7-ED1C-4C1A-9541-A3FA55E9D8B3

Q39240990-425AFD17-A69E-48B5-ABAE-2F6E21334479

Q39240990-4FB050C6-58F4-487E-9E67-2EFD86DB4F3A

Q39240990-57BC5CD8-E91B-4DC1-9776-52BFBF439EBC

Q39240990-59A189D4-4316-41AC-91B5-F5A789E473AF

Q39240990-64664559-D90E-4953-8B27-BA71EE1471E8

Q39240990-89233508-D6FE-4D42-82E6-885B6B45A524

P2860

Q39240990-10C6AA23-854F-4A31-9D72-1F52205C3419

Q39240990-1F97AB34-F99E-41A8-AD51-6EEDE5730938

Q39240990-25D48E59-7A00-41FF-8441-F0A3EC070D58

Q39240990-26ED8F8E-350D-464D-8093-AF9D3A6003DC

Q39240990-2E7A1373-8114-49CD-98B2-77B5633FFD17

Q39240990-2EEDF913-5294-4001-91F5-50DDF4E77246

Q39240990-325789F9-BE17-41BD-9988-4B87413FA3B3

Q39240990-371F66BF-34CE-4664-BB26-CF1F1DEB5767

Q39240990-420E7E3E-FD8D-4592-976A-AA06E2E4ACAB

Q39240990-4F02FF09-5187-4B01-B049-DCB43CFD29C8

P304

Q39240990-FED5E469-EC8E-4063-9149-E60A7ECDFC41

P31

Q39240990-43AC94E5-8E58-49C5-90CD-1956A1D97C0A

P356

Q39240990-01E8ABE3-DFB7-4F29-A165-81FF50410DC1

P407

Q39240990-F94C5A9C-769C-4801-A0C5-991804190998

P433

Q39240990-B4F79762-6C2D-480E-A34C-392A7F86CCC7

P478

Q39240990-838827CA-AF43-4504-955D-898DE556B50B

P577

Q39240990-990E8936-C9F6-4275-9B64-497D51166715

P698

Q39240990-7045652A-31C1-4170-B0D8-6411A92EA0F7

P932

Q39240990-A1349714-29D5-4D67-B6FC-3368C1FC44E0

P356

P1433

P1476

Farnesoid X receptor inhibits ...... s development of liver cancer.

@en

P2093

Angela Mayor

http://www.w3.org/2001/XMLSchema#string

David Moore

http://www.w3.org/2001/XMLSchema#string

Emily Sullivan

http://www.w3.org/2001/XMLSchema#string

Gretchen Darlington

http://www.w3.org/2001/XMLSchema#string

Il-Hwa Hong

http://www.w3.org/2001/XMLSchema#string

Jingling Jin

http://www.w3.org/2001/XMLSchema#string

Milton Finegold

http://www.w3.org/2001/XMLSchema#string

Nikolai A Timchenko

http://www.w3.org/2001/XMLSchema#string

Polina Iakova

http://www.w3.org/2001/XMLSchema#string

Sayee Anakk

http://www.w3.org/2001/XMLSchema#string

P2860

Novel insights into the INK4-CDK4/6-Rb pathway: counter action of gankyrin against INK4 proteins regulates the CDK4-mediated phosphorylation of Rb

The oncoprotein gankyrin binds to MDM2/HDM2, enhancing ubiquitylation and degradation of p53

Liver tumors escape negative control of proliferation via PI3K/Akt-mediated block of C/EBP alpha growth inhibitory activity

The crystal structure of gankyrin, an oncoprotein found in complexes with cyclin-dependent kinase 4, a 19 S proteasomal ATPase regulator, and the tumor suppressors Rb and p53

Combined deletion of Fxr and Shp in mice induces Cyp17a1 and results in juvenile onset cholestasis.

Liver regeneration after partial hepatectomy: critical analysis of mechanistic dilemmas.

Alterations in xenobiotic metabolism in the long-lived Little mice.

Gankyrin plays an essential role in Ras-induced tumorigenesis through regulation of the RhoA/ROCK pathway in mammalian cells.

Overexpression of p28/gankyrin in human hepatocellular carcinoma and its clinical significance

Intracellular signaling and hepatocellular carcinoma.

P304

1098-1106

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.26146

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23172628

http://www.w3.org/2001/XMLSchema#string

P932

3649861

http://www.w3.org/2001/XMLSchema#string